CGON CG Oncology Forecast, Technical & Fundamental Analysis
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
CGON is expected to report earnings to fall 15.49% to -60 cents per share on November 12
Q3'26
Est.
$-0.60
Q1'26
Missed
by $0.11
Q4'25
Missed
by $0.07
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.12
The last earnings report on May 08 showed earnings per share of -70 cents, missing the estimate of -60 cents. With 141.25K shares outstanding, the current market capitalization sits at 6.62B.
A.I.dvisor indicates that over the last year, CGON has been loosely correlated with ORKA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then ORKA could also see price increases.
CGON sees its Stochastic Oscillator ascends from oversold territory
On September 02, 2026, the Stochastic Oscillator for CGON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 24 instances where the indicator left the oversold zone. In of the 24 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in of 136 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 97 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CGON turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CGON broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.431) is normal, around the industry mean (20.572). P/E Ratio (0.000) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (444.169).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
